Literature review on hepatoprotective effects of diosgenin: possible mechanisms of action.
diabetes mellitus
diosgenin
fatty liver
liver fibrosis
liver injury
steatohepatitis
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
05
2023
accepted:
31
08
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Liver diseases are among the major causes of death worldwide. Alcohol consumption, obesity, diabetes mellitus, viral infection, and drug-induced liver injury are common risk factors for the development of liver diseases. Diosgenin is a herbal steroidal sapogenin with hepatoprotective properties. This phytosteroid modulates lipid profile and prevents liver injury and fibrosis, metabolic associated fatty liver disease (MAFLD), steatohepatitis, and diabetes mellitus. Different mechanisms have been presented underlying the therapeutic properties of diosgenin. Diosgenin with antioxidant activity and ability to inhibit pro-inflammatory and apoptotic mediators as well as modulating gut microbiota is able to protect the liver. This literature overview summarizes the previously published studies regarding the hepatoprotective function of diosgenin against liver injury in different conditions with an emphasis on possible underlying mechanisms.
Identifiants
pubmed: 37767400
doi: 10.3389/fphar.2023.1226548
pii: 1226548
pmc: PMC10520708
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1226548Informations de copyright
Copyright © 2023 Mohseni-Moghaddam, Khanmohammadi and Roghani.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Atherosclerosis. 2015 Mar;239(1):192-202
pubmed: 25617860
J Agric Food Chem. 2021 Apr 7;69(13):3982-3991
pubmed: 33755449
Life Sci. 2020 Nov 1;260:118182
pubmed: 32781063
J Hepatol. 2019 Jan;70(1):151-171
pubmed: 30266282
Diabet Med. 2007 Jan;24(1):1-6
pubmed: 17227317
J Hepatol. 2023 Aug;79(2):516-537
pubmed: 36990226
Science. 2004 Feb 20;303(5661):1201-4
pubmed: 14976318
Gastroenterology. 1999 Jun;116(6):1413-9
pubmed: 10348825
Saudi J Biol Sci. 2021 Jan;28(1):1026-1032
pubmed: 33424396
Life Sci. 2018 Mar 1;196:28-37
pubmed: 29339101
Immunol Endocr Metab Agents Med Chem. 2009 Mar;9(1):18-29
pubmed: 20174593
Diabetes Metab Syndr Obes. 2021 Sep 15;14:4015-4030
pubmed: 34552341
Nutrients. 2018 May 19;10(5):
pubmed: 29783752
Microb Pathog. 2020 Sep;146:104243
pubmed: 32389705
Clin Gastroenterol Hepatol. 2023 Jan;21(1):223-225.e3
pubmed: 34728405
Pharmacol Res. 2018 Mar;129:177-187
pubmed: 29175112
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Aug;1864(8):1124-1133
pubmed: 31054325
Toxicol Pathol. 2005;33(1):41-51
pubmed: 15805055
Pharmaceutics. 2022 Aug 12;14(8):
pubmed: 36015311
Food Funct. 2019 Nov 1;10(11):7022-7036
pubmed: 31687707
Front Pharmacol. 2023 Apr 11;14:1180263
pubmed: 37113761
Oxid Med Cell Longev. 2022 May 29;2022:1035441
pubmed: 35677108
West Indian Med J. 2005 Mar;54(2):97-101
pubmed: 15999877
Oxid Med Cell Longev. 2020 Mar 6;2020:3153082
pubmed: 32215172
Nutrients. 2022 Nov 24;14(23):
pubmed: 36501024
Phytomedicine. 2023 Mar;111:154661
pubmed: 36682299
Front Pharmacol. 2022 Apr 25;13:854790
pubmed: 35548355
Gut. 2023 Jul 25;:
pubmed: 37491159
Prostaglandins Other Lipid Mediat. 2021 Oct;156:106580
pubmed: 34252545
World J Hepatol. 2018 Jan 27;10(1):1-7
pubmed: 29399273
Phytomedicine. 2014 Sep 15;21(10):1154-61
pubmed: 24889525
Med Sci Monit. 2018 Jan 12;24:246-253
pubmed: 29329279
J Clin Exp Hepatol. 2019 Sep-Oct;9(5):607-618
pubmed: 31695251
World J Gastroenterol. 2010 Dec 21;16(47):5936-45
pubmed: 21157969
Toxicol Mech Methods. 2011 Jul;21(6):473-8
pubmed: 21417628